The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

24 Sep 2020 17:21

RNS Number : 0633A
Premier Veterinary Group PLC
24 September 2020
 

 

 

PREMIER VETERINARY GROUP PLC

 

("PVG", the "Company" or the "Group")

 

Results of General Meeting and Annual General Meeting

Delisting

 

 

 

 

London, UK, 24 September 2020 - Premier Veterinary Group PLC (LSE: PVG) announces that, at the Annual General Meeting of the Company held today, all resolutions put to shareholders were duly passed.

 

In addition, at the subsequent General Meeting of the Company also held today, all resolutions put to shareholders were duly passed. This General Meeting was held, inter alia, to approve the Resolutions upon which the Acquisition of AHCL was conditional, as announced on 13 August 2020 (the "Announcement") and details of which were set out in a circular to shareholders dated 1 September 2020 (the "Circular").

 

Capitalised terms and expressions used in this announcement have the meanings given to them in the Announcement.

 

Following completion of the Acquisition, Simplyhealth and persons presumed to be acting in concert for the purposes of the City Code (the "Simplyhealth Concert Party"), will hold the Convertible Loan which upon conversion (or if SH Warrants are issued, on the exercise of the SH Warrants) would result in 15,346,949 Ordinary Shares being held by the Simplyhealth Concert Party, representing approximately 49.99 per cent. of the enlarged issued ordinary share capital (assuming that the Existing Warrants, New Warrants and Director Share Options had not been exercised at the point of such conversion). Under Rule 9 of the City Code, the Simplyhealth Concert Party would normally be obliged to make an offer to all Shareholders to acquire their Ordinary Shares for cash upon the issue of the Conversion Shares. A submission has been made to the Panel seeking a waiver of this obligation, subject to the approval of the Shareholders on a poll of the First Whitewash Resolution at the General Meeting.

 

Simplyhealth - First Waiver

 

Resolution 1 in the Notice of General Meeting, being an ordinary resolution to be voted on by the Independent Shareholders to approve the waiver by the Takeover Panel of the obligation that would otherwise arise for Simplyhealth to make a general offer for the Company under the Rule 9 of the Takeover Code ("Whitewash Resolution"), was passed on a poll with 11,519,572 votes of Independent Shareholders, in favour and 13 votes against.

 

Following completion of the Acquisition, Simplyhealth and persons presumed to be acting in concert for the purposes of the City Code (the "Simplyhealth Concert Party"), will hold the Convertible Loan which upon conversion (or if SH Warrants are issued, on the exercise of the SH Warrants) would result in 15,346,949 Ordinary Shares being held by the Simplyhealth Concert Party, representing approximately 49.99 per cent. of the enlarged issued ordinary share capital (assuming that the Existing Warrants, New Warrants and Director Share Options had not been exercised at the point of such conversion).

 

Existing Concert Party - Second Waiver

 

Resolution numbered 2 in the Notice of General Meeting, being an ordinary resolution to be voted on by the Independent Shareholders to approve the waiver by the Takeover Panel of the obligation that would otherwise arise for the Existing Concert Party to make a general offer for the Company under the Rule 9 of the Takeover Code ("Whitewash Resolution"), was passed on a poll with 4,371,264 votes of Independent Shareholders, in favour and 13 votes against.

 

In the Circular, the holdings of each member of the Existing Concert Party at the date of the Circular and immediately following the exercise of the Existing Warrants, the New Warrants and Director Share Options (assuming that Simplyhealth has not converted the Convertible Loan and no Conversion Shares have been issued and no Existing Employee Share Options have been exercised) were as follows:

 

 

 

 

 

 

 

 

 

 

 

 

Existing Concert Party

 

 

 

 

 

 

 

 

Number of Existing Ordinary Shares

 

 

 

 

 

 

 

 

Percentage of Existing Ordinary Shares

 

 

 

 

 

 

Number of Existing Warrants, New Warrants and Directors Share Options

Maximum number of Ordinary Shares after exercise of Existing Warrants, New Warrants and Director Share Options

 

Percentage of Ordinary Shares after exercise of Existing Warrants, New Warrants and Director Share Options

Raj Uppal

5,143,638

33.51

-

5,143,638

30.66

Tracey Uppal

277,500

1.81

-

277,500

1.65

Dominic Tonner

1,799,670

11.73

279,035

2,078,705

12.39

BSFL

-

-

920,816

920,816

5.49

Crossroads

-

-

230,204

230,204

1.37

 

7,220,808

47.05

1,430,055

8,650,863

51.56

 

As can be seen from the table above, the net effect of exercise of the Existing Warrants, the New Warrants and the Director Share Options at any time prior to the conversion of the Convertible Loan and issue of the Conversion Shares, and the exercise of any Existing Employee Share Options, is to increase the aggregate holding of the Existing Concert Party from 47.05 per cent. of the existing issued share capital to 51.56 per cent. of the Post Exercise Issued Share Capital.

 

Subsequent to the date of the Circular, Raj Uppal and his wife, Tracey Uppal, have sold 60,000 and 12,500 ordinary shares respectively. As such the holdings of Raj Uppal and Tracey Uppal at the date of this announcement are 5,083,638 and 265,000 respectively.

 

Acquistion of Simplyhealth

 

In addition the passing of the necessary resolutions at the General meeting today, the Company has also received today confirmation from the CMA that it does not intend to investigate the Acquisition further. This means that, subject to the Delisting, there is now no hindrance to the completion of the Acquisition and the Company will seek to complete it as soon as practicable.

 

Delisting

 

Further to the announcements made by Premier Veterinary Group plc on 13 August 2020 and 2 September 2020, PVG can confirm today that, following an application by the Company it expects the Financial Conduct Authority to cancel the listing of PVG's Ordinary Shares on the standard listing segment of the Official List and the London Stock Exchange to cancel the trading of PVG's Ordinary Shares on the London Stock Exchange's main market for listed securities, in each case with effect from 8:00 a.m. (London time) tomorrow, 25 September 2020.

 

 

-Ends-

 

For further information, please contact:

Premier Veterinary Group plc

www.premiervetgroup.co.uk

Dominic Tonner, Chief Executive Officer

+44 (0)117 970 4130

Andy Paull, Chief Financial Officer

 

 

WH Ireland Limited (Broker)

www.whirelandplc.com

Mike Coe / Chris Savidge

+44 (0) 207 220 1666

 

For further details go to: www.premiervetgroup.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSESFMLESSEEU
Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.